TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02438384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
Study: NCT04126070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
Study: NCT02438384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone follow-up
Description: The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
Study: NCT03143907

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
Description: MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
Description: MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
Study: NCT02889289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xbox One Kinect Gaming
Description: The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities.
Study: NCT00771043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TYSABRI and AVONEX
Description: TYSABRI and AVONEX treatment per package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TYSABRI and AVONEX
Description: TYSABRI and AVONEX treatment per package insert.
Study: NCT04065074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Extended-release 32 mg FX006 IA injection
Study: NCT03345160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut Flour
Description: open label oral immunotherapy
Study: NCT01103154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Description: 6.25mg per day, increase to 6.25mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nadolol + ISMN
Description: nadolol 40-80mg ISMN 10-20mg
Study: NCT01521871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin wound closure by tissue glue
Description: The glue is used both as closure device and as wound dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin wound closure by conventional suture + dressing
Description: Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
Study: NCT00948857

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: 25 mg PO TID
Study: NCT00948857

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded placebo
Study: NCT04200196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fabrique à histoire
Description: Fabrique à histoire is a participatory entertainment method. Children of this arm going to create and listening a story before and during the venous puncture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: It is a passive entertainment method. Children of this arm going to do habitual activities before and during the venous puncture, like to sing, blow up a balloon, to play with recreational thing, etc.
Study: NCT03419897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study: NCT04511871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCT303-406
Description: Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.
Study: NCT02617407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livionex® Dental Gel
Description: Oral application Dental Plaque, Gingivitis and Oral Microbiome Control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PreviDent 5000 plus/Tom's of Maine Children's toothpaste
Description: Oral application for Dental Plaque, Gingivitis and Oral Microbiome Control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kolibree Toothbrush
Description: Electric Toothbrush

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kolibree Toothbrush
Description: Electric Toothbrush
Study: NCT03300141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Veridical Visual Feedback
Description: Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Veridical Visual Feedback
Description: Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Visual Feedback
Description: Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Visual Feedback
Description: Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Comparative Reaching Task
Description: Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
Study: NCT02972034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT02652585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
Study: NCT02831049

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval-extinction
Description: Memory retrieval-extinction is a novel behavioral procedure for reduction of craving and drinking in problem drinkers.
Study: NCT03435367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Program
Description: VR with head mounted display (HMD) and headphones.
Study: NCT03435367

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPad Tablet
Description: iPad with headphones
Study: NCT02324790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNAP® Sleep Therapy System
Description: The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
Study: NCT02831049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-extinction
Description: Memory retrieval-extinction is a novel behavioral procedure for reduction of craving and drinking in problem drinkers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol-related cues
Description: Alcohol related cues
Study: NCT04533451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02831049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-related cues
Description: Alcohol related cues
Study: NCT04533451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Ancillary studies
Study: NCT04310449

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft and customized healing abutment
Description: Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Connective tissue grafts from the hard palate will be placed at the implant sites in a supraperiosteal partial dissection prepared at the buccal aspect. Sutures will be used to stabilize the graft, followed by customized healing abutment. Flowable composite will be injected at the gingival margin level to adapt to the sandblasted abutment, taking the shape of the socket at the marginal gingiva. Buccal groove will be made after the polymerization of this material for easier application. The abutments will be removed for final configurations of the apical part mimicking the emergence profile of the extracted tooth and finishing with laboratory discs and burs. The custom healing screw will be screwed to the implant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual zone concept and customized healing abutment
Description: Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Followed by bone grafting following dual zone concept and customized healing abutment.
Study: NCT02490956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Verorab® (PVRV; Purified Vero Cell Vaccine)
Description: * Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363
Study: NCT04533451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01527305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
Study: NCT04161092

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver transplantation Ltx
Description: Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.

Intervention type: OTHER
Group type: OTHER
Intervention: Best alternative care
Description: All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
Study: NCT02963571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior percutaneous pedicle screw internal fixation
Description: The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
Study: NCT01267370

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy polysaccharide fiber
Description: Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and \> 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy polysaccharide fiber
Description: Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and \> 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)
Study: NCT02831049

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Soft-drink related cues
Description: Soft drink related cues
Study: NCT03581292

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT01279720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of transduced cells
Description: Intravenous infusion of transduced cells
Study: NCT03115216

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FLA-CEIOL
Description: Femtosecond laser-assisted cataract extraction and intraocular lens placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEIOL
Description: Manual cataract extraction and intraocular lens placement
Study: NCT04309890

Intervention type: OTHER
Intervention: Arabic version of the Overactive Bladder Symptom Score Questionnaire
Description: All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
Study: NCT04268329

Intervention type: OTHER
Group type: OTHER
Intervention: Educational website
Description: A website is used to educate patients and family members about head and neck cancer.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational website
Description: A website is used to educate patients and family members about head and neck cancer.
Study: NCT03116828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine Acetate
Description: eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine Acetate
Description: eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
Study: NCT00024024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebimastat
Study: NCT02547038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole+bismuth+tetra+metro
Description: pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (panto+amox+clar+metr)+(panto+amox)
Description: a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
Study: NCT00945347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miglustat
Description: Nasal instillation of miglustat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal instillation of placebo matching in appearance with the Miglustat instillation
Study: NCT04976673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
Study: NCT00964665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albinterferon alfa-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albinterferon alfa-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albinterferon alfa-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albinterferon alfa-2b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys®
Study: NCT05345574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine infusion
Description: dexmedetomidine as anaesthetic adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil infusion
Description: remifentanil as anaesthetic adjuvant
Study: NCT03278717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib is a PARP inhibitor, targeting DNA repair processes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a PARP inhibitor, targeting DNA repair processes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.